Loeb Partners Corp lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 10,100 shares of the company’s stock after selling 250 shares during the period. Loeb Partners Corp’s holdings in Eli Lilly and were worth $831,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Joel Isaacson & Co. LLC grew its position in Eli Lilly and by 1.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares in the last quarter. Russell Investments Group Ltd. grew its position in Eli Lilly and by 7.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock valued at $55,258,000 after buying an additional 48,706 shares in the last quarter. Stephens Inc. AR grew its position in Eli Lilly and by 4.5% in the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after buying an additional 1,901 shares in the last quarter. Blair William & Co. IL grew its position in Eli Lilly and by 13.1% in the 1st quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock valued at $21,974,000 after buying an additional 30,299 shares in the last quarter. Finally, Capital Advisors Inc. OK grew its position in Eli Lilly and by 28.4% in the 1st quarter. Capital Advisors Inc. OK now owns 3,711 shares of the company’s stock valued at $312,000 after buying an additional 820 shares in the last quarter. Institutional investors and hedge funds own 75.77% of the company’s stock.

A number of brokerages recently issued reports on LLY. Berenberg Bank reiterated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research report on Friday, August 4th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet lowered shares of Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. BMO Capital Markets reiterated an “underperform” rating and issued a $73.00 target price on shares of Eli Lilly and in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $88.07.

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total transaction of $17,730,300.00. Following the transaction, the insider now owns 124,265,804 shares in the company, valued at approximately $10,491,761,831.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 825,000 shares of company stock worth $68,456,650 in the last quarter. 0.20% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/11/loeb-partners-corp-sells-250-shares-of-eli-lilly-and-company-lly.html.

Shares of Eli Lilly and Company (NYSE LLY) opened at 82.92 on Monday. The firm’s 50-day moving average is $80.99 and its 200-day moving average is $82.04. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The stock has a market capitalization of $87.48 billion, a price-to-earnings ratio of 35.88 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the business posted $0.86 EPS. Eli Lilly and’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. The ex-dividend date was Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.